Sam Fazeli

Joanne Hsu, Director of the University of Michigan Surveys of Consumers, reveals an uptick in consumer sentiment and its economic implications. Shana Sissel, President and CEO of Banríon Capital Management, shares her take on market volatility and investment strategies. Sam Fazeli, Senior Pharmaceuticals Director at Bloomberg Intelligence, discusses recent developments in the biotech industry, including the Mpox outbreak. Ana Cabral, CEO of Sigma Lithium, highlights the company's sustainable mining practices, essential for the green energy transition.

Sam Fazeli, Director of Research at Bloomberg Intelligence with a PhD in pharmacology, tackles the concerning rise in vaccine hesitancy, particularly for childhood immunizations. He discusses the alarming implications of appointing a vaccine-skeptic to a key health position, highlighting the historical context and recent measles outbreaks. Fazeli emphasizes the need for transparency in vaccine approval processes to build public trust and explores how health policies can either enhance or undermine vaccine uptake amid political pressures.

Mandeep Singh, senior tech analyst, shares insights on Alphabet's strong earnings amid Meta's AI concerns. Sam Fazeli discusses Eli Lilly's challenges in the pharmaceutical market. Corey Cantor highlights the impact of U.S. presidents on EV fuel economy standards. Carmen Arroyo reveals the fragility of the commercial mortgage-backed securities market, particularly in U.S. office spaces. Alison Williams analyzes UBS's earnings, while Rhett Buttle emphasizes business leaders' roles in advocating for secure elections, showcasing the intersection of finance and civic responsibility.

Woo Jin Ho, a Senior Technology Analyst, discusses the shocking resignation of Super Micro's auditor and its impact on the AI market. Alison Williams analyzes UBS's strong performance compared to European banks, showcasing its robust equities business. Sam Fazeli dissects Eli Lilly's disappointing earnings and the challenges they face with obesity drug demand. Mandeep Singh highlights Google's impressive performance in a competitive cloud market. Laura Davison shares insights on Puerto Rico's increasing political significance in U.S. elections, including recent controversies and voter integrity issues.

Joining the discussion are Sam Fazeli, Director of Research at Bloomberg Intelligence, who shares insights from a study showing Eli Lilly's weight-loss drug significantly lowers diabetes risk. Mary Ross Gilbert analyzes Macy's and TJX earnings, revealing shifts in consumer habits. Jennifer Bartashus highlights Target's impressive sales recovery through strategic initiatives. They also touch on potential retail mergers impacting convenience stores, all while keeping an eye on the evolving retail landscape amidst economic pressures.

Sam Fazeli, Director of Research for Global Industries at Bloomberg Intelligence, reveals how Eli Lilly’s Zepbound drug significantly reduces diabetes risk. Craig Trudell discusses the European Union's looming 9% tariff on Tesla imports from China, raising concerns about market competitiveness. Dryden Pence shares insights on current market dynamics and investment strategies, including how labor data and consumer trends are shifting the landscape, while also highlighting opportunities in AI venture capital.

Sam Fazeli discusses Eli Lilly acquiring Morphic for $3.2 billion. Mandeep Singh talks about Microsoft and Apple stepping back from OpenAI roles. George Ferguson covers Delta Airlines earnings. Tim Craighead highlights 10 companies to watch in 3Q. Martin Tengler explores the importance of hydrogen in a green future.

Sam Fazeli discusses Eli Lilly acquiring Morphic. Sean O'Hara talks about the ETF market. Jared Dillian advises investors. The show covers pharmaceutical acquisitions, market stability, green hydrogen, and investment strategies.

Biotech Hangout hosts discuss Biden's capital gains tax proposal, FTC's non-compete ban, Q1 earnings reports, Acrivon's oncology data, ImmunityBio's FDA approval, and financings like Xaira Therapeutics $1B raise. They also debate liked vs unliked CEOs and delve into innovative biotech approaches in depression and obesity treatment, as well as biotech deals and investments.

Sean Scanlon, State Comptroller for Connecticut, discusses Connecticut finances and fiscal spending. Sam Fazeli talks about weight loss drug development and vaccine development. Matt Smith discusses inflationary trends, market outlook, and attractiveness in yields. Philip Richter discusses the impact of higher interest rates on the collector car market.